CUSIP 92764N102 · who reports it, how much, and how much it matters to them
22 of the 720 hedge fund managers we track reported shares of Vir Biotechnology, Inc. (Nasdaq: VIR) on Form 13F for 30 June 2026. Between them they reported USD 166m. The largest position belongs to POINT72 Asset Management, at USD 58m. The manager with the most riding on it is Superstring Capital Management, where it is 5.5% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | POINT72 Asset Management17 funds on PPLI.com | USD 58m | 0.1% |
| 2 | Boxer Capital Management1 fund on PPLI.com | USD 19m | 1.4% |
| 3 | Hudson Bay Capital Management8 funds on PPLI.com | USD 14m | 0.0% |
| 4 | Two Sigma Investments35 funds on PPLI.com | USD 11m | 0.0% |
| 5 | Sio Capital Management4 funds on PPLI.com | USD 11m | 1.8% |
| 6 | Renaissance Technologies13 funds on PPLI.com | USD 10m | 0.0% |
| 7 | Citadel Advisors32 funds on PPLI.com | USD 10m | 0.0% |
| 8 | Superstring Capital Management1 fund on PPLI.com | USD 8.7m | 5.5% |
| 9 | Weiss Asset Management5 funds on PPLI.com | USD 5.7m | 0.1% |
| 10 | Walleye Capital8 funds on PPLI.com | USD 5.2m | 0.0% |
| 11 | D. E. Shaw & Co.15 funds on PPLI.com | USD 4.2m | 0.0% |
| 12 | Eversept Partners3 funds on PPLI.com | USD 1.6m | 0.1% |
| 13 | Edgestream Partners5 funds on PPLI.com | USD 1.4m | 0.0% |
| 14 | Engineers Gate Manager1 fund on PPLI.com | USD 1.3m | 0.0% |
| 15 | Squarepoint Ops7 funds on PPLI.com | USD 1.3m | 0.0% |
| 16 | Empyrean Capital Partners2 funds on PPLI.com | USD 1.2m | 0.0% |
| 17 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 753,000 | 0.0% |
| 18 | LMR Partners2 funds on PPLI.com | USD 691,000 | 0.0% |
| 19 | Millennium Management6 funds on PPLI.com | USD 489,000 | 0.0% |
| 20 | Brevan Howard Capital Management39 funds on PPLI.com | USD 220,000 | 0.0% |
| 21 | The Quarry1 fund on PPLI.com | USD 469 | 0.0% |
| 22 | Summit Global Investments1 fund on PPLI.com | USD 355 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Superstring Capital Management | USD 8.7m | 5.5% |
| 2 | Sio Capital Management | USD 11m | 1.8% |
| 3 | Boxer Capital Management | USD 19m | 1.4% |
| 4 | Eversept Partners | USD 1.6m | 0.1% |
| 5 | POINT72 Asset Management | USD 58m | 0.1% |
| 6 | Weiss Asset Management | USD 5.7m | 0.1% |
| 7 | Edgestream Partners | USD 1.4m | 0.0% |
| 8 | Hudson Bay Capital Management | USD 14m | 0.0% |
| 9 | Empyrean Capital Partners | USD 1.2m | 0.0% |
| 10 | Walleye Capital | USD 5.2m | 0.0% |
Vir Biotechnology, Inc. trades under the symbol VIR on the Nasdaq. Its CUSIP, the code used on Form 13F, is 92764N102.
22 of the 720 hedge fund managers PPLI.com tracks reported Vir Biotechnology, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by POINT72 Asset Management (USD 58m), Boxer Capital Management (USD 19m), Hudson Bay Capital Management (USD 14m), Two Sigma Investments (USD 11m) and Sio Capital Management (USD 11m).
22 managers in our coverage reported it, and between them they run 236 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Superstring Capital Management, where the position was 5.5% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Vir Biotechnology, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.